An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA)
Phase of Trial: Phase IV
Latest Information Update: 08 Jul 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ORZORA
- Sponsors AstraZeneca
- 30 Sep 2016 Planned number of patients changed from 250 to 275.
- 30 Sep 2016 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.
- 30 Sep 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Jan 2019.